Species predicted to react based on 100% sequence homology:Monkey
Specificity / Sensitivity
LRIG1 Antibody recognizes endogenous levels of total LRIG1 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
原厂资料:
Homology
Species predicted to react based on 100% sequence homology:Monkey
Specificity / Sensitivity
LRIG1 Antibody recognizes endogenous levels of total LRIG1 protein.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).